Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

AAV Vector Manufacturing for Paul-Ehrlich-Institut (PEI) Submissions

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

AAV Vector Manufacturing for Paul-Ehrlich-Institut (PEI) Submissions

CELL & GENE | RNA | BIOLOGICS

A close-up of a Pall Corporation single-use bioreactor system in a cleanroom environment, showing the control panel, vessel with cell culture media, and tubing.

Proven Intelligence in European Regulatory CMC.

Executive Summary

Manufacturing Adeno-Associated Virus (AAV) vectors for clinical evaluation in Germany requires a robust Chemistry, Manufacturing, and Controls (CMC) strategy aligned with the specific requirements of the Paul-Ehrlich-Institut (PEI) for Advanced Therapy Medicinal Products (ATMPs). This involves rigorous process development, phase-appropriate analytical qualification, and comprehensive documentation to support an Investigational Medicinal Product Dossier (IMPD) submission. Our approach focuses on generating a well-characterized vector with a consistent purity and potency profile, directly addressing PEI’s expectations for product quality.

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

Frequently Asked Questions

What are the primary CMC considerations when preparing an AAV vector program for an IMPD submission to the Paul-Ehrlich-Institut?

The PEI places significant emphasis on the characterization of the ATMP, including the ratio of full to empty capsids, the qualification of potency assays, and the full traceability of all raw materials used in the manufacturing process. A comprehensive data package demonstrating process consistency and product purity is expected.

How does Franklin Biolabs ensure AAV vector analytics meet European ATMP guidelines?

We develop and qualify all bioanalytical and potency assays in a phase-appropriate manner under GxP conditions. Our analytics group provides comprehensive characterization, including vector genome titer, capsid titer, aggregation analysis, and residual impurity testing, to build a data package that satisfies both PEI and broader ICH guidelines.

Can a single AAV manufacturing process support clinical trials in both the EU and the US?

Yes, a well-designed process development strategy can support multi-regional submissions. By building a process with ICH guidelines as the foundation, the resulting CMC data package can be adapted for both an FDA IND and a PEI IMPD, streamlining the path to global clinical trials.

Navigating the regulatory pathway for next-generation therapeutics in Europe demands a specific focus on the requirements of national competent authorities like Germany’s Paul-Ehrlich-Institut. The PEI’s oversight of ATMPs necessitates a scalable manufacturing process with meticulous documentation and control to ensure product consistency from preclinical batches to clinical-grade material.

Our core scientific leadership’s track record, which includes a 100% successful IND rate since 2019, was established prior to the formal launch of Franklin Biolabs in 2024. This deep experience informs our approach to developing manufacturing processes designed for regulatory acceptance and provides continuity for programs transitioning from academic collaborations.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Aligning Manufacturing with PEI Expectations

A successful IMPD submission hinges on a comprehensive CMC data package. Our process development is structured to address key areas of regulatory scrutiny.

  • Vector Purity and Characterization: We employ platform analytical methods to quantify key quality attributes, such as the percentage of full capsids and the removal of process-related impurities.

  • Potency Assay Strategy: We design and qualify in vitro cell-based potency assays that reflect the vector’s mechanism of action, a focal point for PEI review.

  • Process Consistency: Utilizing scalable suspension platforms in single-use bioreactors from 2L to 500L+, we establish a consistent and reproducible manufacturing train, generating data that demonstrates process control.

De-Risking through Controlled Biodistribution

A central concern for regulatory bodies is understanding and controlling the in vivo behavior of the vector. The ability to limit non-target tissue biodistribution is a significant factor in the overall risk assessment. Scientific investigations demonstrating methods to mitigate off-target effects, such as liver uptake for CNS-directed vectors, provide a strategic framework for de-risking a clinical program (PMID: 36320416). This principle of control is integral to building a compelling safety narrative for PEI and other agencies.

Our operational capacity, housed within a >100,000 sq ft facility, and our experience through collaborations, including with our partners, provide the foundation to execute these complex manufacturing campaigns. We deliver a well-characterized AAV vector and the supporting documentation required to accelerate the path toward European clinical trials.

This targeted approach to manufacturing is a component of our broader capabilities detailed in our central resource on Large-Scale AAV Manufacturing and Process Development.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities